** Shares of medtech firm Neuronetics STIM.O down 18.8% at $2.89 post-market as co seeks equity raise
** Malvern, Pennsylvania-based co, which offers its NeuroStar Therapy to treat major depressive disorder, launches stock offering
** Targeted deal size not disclosed
** Co has ~55.65 mln shares outstanding for roughly $200 mln market value and ~27 mln shares of public float, according to LSEG data
** Canaccord Genuity is sole bookrunner for offering
** STIM shares on Thurs rose 8.9% to close at $3.56. YTD, stock up 121%
** Avg rating among 4 analysts is "buy" with $3 median PT - LSEG
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。